Doxycycline vs. Penicillin G Benzathine for the Treatment of Syphilis in Patients with HIV



OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES

Oklahoma State University Medical Center | Department of Pharmacy¹, Department of Internal Medicine²

Cole Eichelberger, PharmD¹; Isaac Nichols, PharmD¹; Bryan Bozell, PharmD, BCPS, AAHIVP¹,²

BACKGROUND

- Syphilis is an infection which can be transmitted through sexual intercourse, perinatally, or by coming into contact with a syphilitic chancre
- The untreated disease can progress to various stages over time and is caused by the spirochete Treponema pallidum
- Syphilis is associated with an enhanced risk of acquiring HIV, so appropriate treatment is important for both patients with and without concurrent HIV infection
- Historically, penicillin G benzathine has been the primary agent used to treat syphilis infections, with doxycycline being an alternative agent for patients who cannot tolerate penicillin antibiotics
- The efficacy of doxycycline in treating syphilis in patients with HIV has not been well documented despite its use as an alternative treatment

OBJECTIVES

- Compare the effectiveness of doxycycline in treating syphilis in the HIV population against the traditional penicillin G benzathine
- Assess appropriateness of therapy for both syphilis and other STIs (sexually transmitted infections)
- Identify commonly reported adverse effects to either agent used to treat syphilis

END POINTS

Primary Endpoint:

Resolution of syphilis infection

Secondary

- Presence of co-infection
- Reported adverse reactions to treatment

METHODS & PRELIMINARY OUTCOMES

This study was conducted as a retrospective chart review consisting of a cohort of patients in which resolution of syphilis infections using penicillin G benzathine or doxycycline will be assessed

Inclusion Criteria


- Age \geq 18 years
- Diagnosed with HIV
- Diagnosis of new or recurrent syphilis
- Documented prescription for doxycycline or penicillin G benzathine

Exclusion Criteria

- treatment
- Age < 18 years
- Insufficient data to determine treatment response (i.e. no


- Neurosyphilis at time of
- Pregnant patients
- repeat RPR)

Sample Size



Primary Endpoint

Resolved



Not Resolved

Doxycycline

Data Collected/Analyzed:

- Gender
- Age
- Race
- Renal function (serum creatinine) at time of treatment
- Allergies to antibiotics with reaction type
- Diagnosed stage of syphilis
- Prescribed antibiotic
- Dose, duration, and route of antibiotic
- HIV viral RNA count
- CD4 count
- Co-infection with other STI
- Presence of opportunistic infection prophylaxis
- MSM status
- Transgender status
- Reported adverse effects
- Initial infection vs. re-infection
- Re-infection vs. incomplete initial treatment
- Active treatment for HIV

Secondary Endpoints

Presence of Co-infection	
Doxycycline	Penicillin G Benzathine
Human Papillomavirus (n=1)	Chlamydia (n=3)
Gonorrhea (n=2)	Gonorrhea (n=6)
Hepatitis C (n=2)	Hepatitis C (n=2)
	Herpes (n=4)
Reported Adverse Reactions to Treatment	
Doxycycline	Penicillin G
	Benzathine
Diarrhea reported in 1	Nausea reported in 1
case	case

CONCLUSIONS & DISCUSSION

- This study is ongoing
- Data analysis is currently in progress
- Penicillin G benzathine group larger than doxycycline group likely due to it being the standard of care
- Resolution of infection occurred in less patients in the doxycycline arm than in the penicillin G benzathine arm
- Difficult to confidently interpret findings due to treatment groups dissimilar in number and infection
- Co-infection not common among either group and appeared to show no correlation to treatment success
- Adverse effects to treatment rarely reported in chart

NEXT STEPS

- Complete data analysis
- Plan to review findings with internal medicine physicians and residents
- Further studies needed to determine if doxycycline is truly inferior to penicillin G benzathine

DISCLOSURES

No authors of this presentation have anything to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation.

REFERENCES

- Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescentopportunistic-infection. Accessed September 23, 2022.
- 2. Syphilis Among Persons with HIV Infection. Centers for Disease Control and Prevention. https://www.cdc.gov/std/treatmentguidelines/syphilis-hiv.htm. Published 2022. Accessed October 10, 2022.
- 3. Khalil G. Ghanem, Emily J. Erbelding, Walter W. Cheng, Anne M. Rompalo, Doxycycline Compared with Benzathine Penicillin for the Treatment of Early Syphilis, Clinical Infectious Diseases, Volume 42, Issue 6, 15 March 2006, Pages e45–e49, https://doi.org/10.1086/500406